Values First Advisors Inc. acquired a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 688 shares of the biotechnology company’s stock, valued at approximately $32,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in RNA. Avoro Capital Advisors LLC raised its stake in shares of Avidity Biosciences by 132.1% in the first quarter. Avoro Capital Advisors LLC now owns 5,825,000 shares of the biotechnology company’s stock worth $148,654,000 after purchasing an additional 3,315,000 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Avidity Biosciences by 4,661.3% during the 1st quarter. Janus Henderson Group PLC now owns 1,242,833 shares of the biotechnology company’s stock worth $31,704,000 after acquiring an additional 1,216,730 shares during the last quarter. RA Capital Management L.P. grew its stake in shares of Avidity Biosciences by 33.7% in the 1st quarter. RA Capital Management L.P. now owns 3,282,180 shares of the biotechnology company’s stock worth $83,761,000 after acquiring an additional 827,647 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Avidity Biosciences by 2,263.7% in the second quarter. D. E. Shaw & Co. Inc. now owns 739,039 shares of the biotechnology company’s stock valued at $30,190,000 after purchasing an additional 707,773 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new position in shares of Avidity Biosciences during the first quarter valued at about $15,467,000.
Avidity Biosciences Stock Performance
Shares of Avidity Biosciences stock opened at $45.11 on Friday. The stock has a market capitalization of $4.95 billion, a price-to-earnings ratio of -15.34 and a beta of 0.89. The company has a fifty day moving average of $44.47 and a 200-day moving average of $37.96. Avidity Biosciences, Inc. has a 52-week low of $4.82 and a 52-week high of $50.78.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. Barclays initiated coverage on shares of Avidity Biosciences in a research note on Wednesday, August 28th. They issued an “overweight” rating and a $63.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 target price on shares of Avidity Biosciences in a research report on Tuesday, August 13th. TD Cowen boosted their price target on shares of Avidity Biosciences from $56.00 to $78.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Chardan Capital raised their price objective on shares of Avidity Biosciences from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, The Goldman Sachs Group started coverage on shares of Avidity Biosciences in a research note on Tuesday, September 24th. They set a “buy” rating and a $59.00 price target for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $62.67.
View Our Latest Stock Report on RNA
Insider Activity
In other Avidity Biosciences news, CEO Sarah Boyce sold 32,880 shares of the stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $44.00, for a total transaction of $1,446,720.00. Following the completion of the sale, the chief executive officer now owns 234,663 shares of the company’s stock, valued at $10,325,172. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Avidity Biosciences news, CEO Sarah Boyce sold 32,880 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $44.00, for a total transaction of $1,446,720.00. Following the completion of the transaction, the chief executive officer now owns 234,663 shares of the company’s stock, valued at $10,325,172. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Tamar Thompson sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $44.98, for a total value of $1,349,400.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 155,543 shares of company stock valued at $6,995,842. 3.68% of the stock is currently owned by company insiders.
Avidity Biosciences Profile
Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.
See Also
- Five stocks we like better than Avidity Biosciences
- How to buy stock: A step-by-step guide for beginners
- Texas Roadhouse Stock Steering for New Highs This Year
- Bank Stocks – Best Bank Stocks to Invest In
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Want to see what other hedge funds are holding RNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report).
Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.